INTRODUCTION {#S1}
============

Lung cancer is epidemic in the U.S. and worldwide, largely related to cigarette smoking ([@R27]; [@R32]; [@R40]). Among smokers, the primary risk factor for developing lung cancer is the presence of chronic obstructive pulmonary disease (COPD) ([@R52]), which is characterized by chronic pulmonary inflammation, airway remodeling, and destruction of lung parenchyma ([@R4]; [@R36]; [@R48]). Several studies have confirmed that COPD is an independent risk factor for lung cancer ([@R41]; [@R49]). We and others have proposed that chronic inflammation, as occurs in COPD, could provide the mechanistic link to explain increased lung cancer risk in these patients ([@R18]; [@R28]; [@R44]). However, the specific inflammatory cells and pathways involved in potentiating lung cancer risk are not well defined.

The nuclear factor (NF)-κB signaling pathway, an elegant system that executes transcriptional responses to cell stress, regulates expression of cytokines, chemokines, adhesion molecules, apoptosis-regulating genes, matrix metalloproteinases, enzymes, and receptors ([@R7]; [@R42]). NF-κB is activated by a number of tumor-promoting agents and is involved in production of proteins that enhance cell survival and proliferation ([@R31]; [@R33]). In humans, NF-κB has been reported to be activated in precancerous lesions and lung cancer specimens obtained by resection or biopsy ([@R47]). We and others have shown that the NF-κB pathway impacts lung tumor development in mice by enhancing epithelial cell survival in both chemical carcinogens and genetic models ([@R26]; [@R44]; [@R46]). Despite recent interest in the role of NF-κB in lung cancer, a number of key questions remain.

In these studies, we asked whether NF-κB provides a mechanistic link between chronic airway inflammation and increased risk of lung carcinogenesis and if so, how persistent NF-κB activation augments tumor formation. To regulate NF-κB in the lungs, we utilized transgenic mice with inducible expression of active IκB kinase β (IKKβ) in airway epithelial cells (*IKTA* mice) ([@R10]). We found that long-term activation of NF-κB resulted in persistent airway inflammation characterized by macrophage and lymphocyte infiltration. Following exposure to chemical carcinogens, *IKTA* mice exhibited enhanced lung tumorigenesis even when lung inflammation was induced after carcinogen exposure. Increased tumor formation in *IKTA* mice was preceded by increased proliferation of airway epithelial cells and enhanced formation of premalignant lesions. Further investigation of the nature of the lung inflammatory cell influx of *IKTA* mice revealed a substantial increase in regulatory T lymphocytes (Tregs). Depletion of these cells resulted in increased numbers of CD8 lymphocytes in the lungs and a reduction of lung tumor formation in *IKTA* mice. Collectively, our findings show that chronic NF-κB-driven inflammation enhances lung tumor formation in a paracrine manner via regulation of key immune cell populations that impact epithelial cell proliferation and survival.

RESULTS {#S2}
=======

Chronic NF-κB-driven airway inflammation enhances urethane-induced lung carcinogenesis {#S3}
--------------------------------------------------------------------------------------

*IKTA* mice express constitutively active IKKβ in Clara cell specific protein (CCSP)-expressing airway epithelium after doxycycline treatment ([@R10]). Addition of 0.5 mg/ml of doxycycline to drinking water resulted in an early neutrophil-predominant inflammatory cell influx during the first 2 weeks followed by a shift in the inflammatory cell profile to a predominance of macrophages and lymphocytes by week 4 of continuous doxycycline as identified in bronchoalveolar lavage (BAL) ([figure 1A](#F1){ref-type="fig"}). This chronic inflammatory profile persisted for at least 4 months of doxycycline treatment. As indicated in [figure 1B](#F1){ref-type="fig"}, this shift in inflammatory pattern occurred despite consistent levels of transgene expression in *IKTA* mice. Although some mice (\<25%) succumbed to acute lung inflammation during the first 2 weeks of doxycycline treatment, after this period mice appeared healthy and active without weight loss or appearance of chronic illness.

We next investigated whether chronic airway inflammation induced by NF-κB activation increases susceptibility to urethane-induced lung tumor formation. We treated mice with a single IP injection of urethane and induced transgene expression by treatment with doxycycline during three different time intervals ([figure 2A](#F2){ref-type="fig"}): 1) beginning 2 weeks prior to urethane and continuing for 3 weeks after urethane injection (week -2--3), 2) beginning at week 4 post-urethane and continuing until harvest at 16 weeks (week 4--16), and 3) beginning 2 weeks prior to urethane and continuing through week 16 after urethane (week -2--16). Prior studies in tet-on models have shown that withdrawal of doxycycline results in loss of transgene expression by 7 days ([@R34]). Wild type (*WT*) mice treated with a similar doxycycline regimen to *IKTA* mice were used as controls in each experiment. Lung tumor formation was assessed in all studies at 16 weeks after urethane injection. In the first experiment, *IKTA* mice treated with doxycycline during weeks -2--3 (tumor initiation and early promotion phase) showed increased tumor formation compared to *WT* mice with or without doxycycline treatment ([figure 2B](#F2){ref-type="fig"}). In the second experiment, *IKTA* mice treated with doxycycline between weeks 4--16 post-urethane (late promotion and progression phase) developed significantly more tumors than *WT* controls ([figure 2C](#F2){ref-type="fig"}). In the third experiment, *IKTA* mice treated with doxycycline for the duration of the experiment (week -2--16) showed a similar increase in tumor numbers to that seen with the week 4--16 regimen ([figure 2D](#F2){ref-type="fig"}). Together, these studies show that epithelial NF-κB activation enhances tumor formation in the lungs. Compared to *IKTA* mice that were treated with doxycycline during weeks -2--3, greater tumor numbers were identified in *IKTA* mice treated with dox during later periods.

Additional urethane-treated *WT* and *IKTA* mice were given doxycycline throughout the experimental period (week -2--16) to confirm the increase in lung tumors by histological examination. Similar to surface tumors, tumor numbers were increased on lung sections from *IKTA* mice compared to *WT* controls ([figure 3A](#F3){ref-type="fig"}). Lung tumors appeared as solid or papillary adenomas without features of adenocarcinoma. Morphometric analysis indicated that the mean tumor diameters were similar between groups ([figure 3B](#F3){ref-type="fig"}). We also evaluated airway inflammation in tumor-containing mice by performing BAL at the time of harvest. Urethane-treated *IKTA* mice showed increased BAL macrophages and lymphocytes compared to *WT* controls ([figure 3C](#F3){ref-type="fig"}), similar to the pattern of chronic inflammation observed in prior experiments in which *IKTA* mice were treated with doxycycline alone ([figure 1A](#F1){ref-type="fig"}).

We measured cellular proliferation by 5-bromodeoxyuridine (BrdU) staining in lung tumors from *WT* and *IKTA* mice treated with urethane and doxycycline from week -2--16. The percentage of BrdU positive cells in tumors from *WT* mice was 1.7±0.4 compared to 1.9±0.6 in tumors from *IKTA* mice ([figure 3D](#F3){ref-type="fig"}). This finding, together with the similarities in tumor size and appearance, indicate that chronic NF-κB activation in our model does not substantially influence growth and progression of established tumors. Instead, these results support the idea that epithelial NF-κB activation affects the promotion phase of tumorigenesis.

NF-κB can function as the sole tumor promoter and increases tumor formation irrespective of genetic background {#S4}
--------------------------------------------------------------------------------------------------------------

While urethane is a complete carcinogen, most carcinogens require a separate promoter agent to achieve tumor formation. 3-methylcholanthrene (MCA), a component of tobacco smoke, is a weak carcinogen that requires the addition of a separate promoter agent like butylated hydroxytoluene (BHT) to reproducibly generate tumors in mice ([@R24]). Prior studies have shown that BHT promotes lung tumors only in strains in which it also induces lung inflammation ([@R6]; [@R23]). We asked whether MCA or BHT induces NF-κB activation in the lungs using NF-κB reporter mice (*HLL*; FVB background) that express luciferase under the control of an NF-κB-dependent promoter ([@R44]; [@R53]). Mice were treated with a single IP injection of MCA or BHT. As shown in [figure 4A](#F4){ref-type="fig"}, MCA failed to induce NF-κB activity in *HLL* mice, but BHT treatment resulted in significantly increased bioluminescence over the chest 7 days after injection. We then asked whether NF-κB activation could substitute for BHT treatment to promote tumor formation after exposure to MCA. *WT* or *IKTA* mice were treated with a single IP dose of MCA plus 8 weekly IP injections of BHT or vehicle (corn oil), with or without continuous doxycycline beginning 2 weeks prior to MCA treatment. In contrast to WT mice, MCA alone was efficient at generating lung tumors in doxycycline-treated *IKTA* mice at 16 weeks after MCA injection. The combination of doxycycline treatment and BHT resulted in an even greater tumor burden after MCA injection in *IKTA* mice ([figure 4B](#F4){ref-type="fig"}). Histological counting of tumors on lung sections confirmed these differences between groups and, similar to the urethane model, no differences in tumor size or appearance were noted (data not shown). Together, these studies show that NF-κB activation can substitute for the tumor promoting effect of BHT in this model.

We next wondered whether NF-κB activation could increase urethane-induced lung tumor formation in the tumor-resistant C57BL/6 strain. In these studies, *WT* and *IKTA* mice (both on C57BL/6 background) were treated with doxycycline followed by a single dose of urethane, and doxycycline was continued until the time of harvest at 6 months. Although lung surface tumor counts were lower in C57BL/6 mice compared to FVB mice, *IKTA* C57BL/6 mice showed an approximate 2.5-fold increase in lung tumors compared to *WT* C57BL/6 mice ([figure 4C](#F4){ref-type="fig"}). Therefore, while NF-κB activation did not overcome the strain-related differences in tumor susceptibility, the relative increase in lung surface tumors was similar between *IKTA* mice on FVB or C57BL/6 backgrounds. These findings support the idea that genetic susceptibility to tumor formation following exposure to a carcinogen can be modified by the presence of an inflammatory lung environment.

NF-κB activation supports development of premalignant lesions in the lungs and augments epithelial cell proliferation and survival {#S5}
----------------------------------------------------------------------------------------------------------------------------------

Since our data indicated that NF-κB activation in airway epithelial cells promotes lung tumor formation, we investigated whether *IKTA* mice (FVB) developed increased numbers of premalignant atypical adenomatous hyperplasia (AAH) lesions. We performed a time-course study in which *IKTA* and *WT* mice (both treated with doxycycline beginning 2 weeks prior to urethane) were harvested at 3, 6, and 9 weeks after urethane treatment. Analysis of lung sections revealed that *IKTA* mice had significantly more AAH lesions than *WT* controls at 6 and 9 weeks post-urethane ([figures 5A,B](#F5){ref-type="fig"}). We identified no differences in size or vascularity of AAH lesions between *WT* and *IKTA* mice at 6 weeks post-urethane. VEGF levels in BAL were similar between the two groups (49±9 pg/ml in *WT* mice and 50±10 pg/ml in *IKTA* mice).

In addition, we measured cell proliferation and apoptosis in the lungs of doxycycline-treated *IKTA* and *WT* mice after urethane treatment. By proliferating cell nuclear antigen (PCNA) staining, we found a marked increase in proliferation of cells in the lung parenchyma (mostly type II alveolar epithelial cells) from *IKTA* mice at 6 weeks after urethane injection ([figures 5C,D](#F5){ref-type="fig"}), correlating with the increase in AAH lesions identified in these mice. Interestingly, by 9 weeks PCNA staining returned to near-baseline in *IKTA* and *WT* mice, indicating that cellular proliferation increased transiently after urethane treatment. In contrast, active caspase-3 staining of these sections obtained 9 weeks after urethane treatment revealed reduced numbers of apoptotic cells in the lungs of *IKTA* mice compared to controls ([figure 5E](#F5){ref-type="fig"}). At 3 and 6 weeks post-urethane, very few active caspase-3 positive cells were identified in either *WT* or *IKTA* mouse lungs. Together, these findings indicate that chronic NF-κB-dependent inflammation creates a pro-tumorigenic environment that supports expansion of initiated epithelial cells into premalignant AAH lesions during the first few weeks after urethane treatment and supports persistence of these lesions by reduced apoptosis at later time points.

Tregs enhance tumor formation in the setting of chronic airway inflammation {#S6}
---------------------------------------------------------------------------

While transgene expression in *IKTA* mice is localized to airway epithelium ([@R10]), we observed increased numbers of AAH lesions and increased proliferation of cells in lung parenchyma after urethane treatment. Therefore, we reasoned that inflammatory cells attracted by mediators produced by airway epithelia, rather than cell-autonomous effects of increased NF-κB activation, might mediate the pro-tumorigenic phenotype of *IKTA* mice. We investigated the lymphocyte influx identified in *IKTA* mice since these cells are increased in the airways of patients with COPD and can influence tumor biology in a variety of ways ([@R12]; [@R20]; [@R22]; [@R29]; [@R35]; [@R43]; [@R50]). We evaluated lymphocyte subsets in the lungs of *IKTA* mice after doxycycline treatment. The total number of CD4+ and CD8+ lymphocytes was increased after doxycycline treatment (data not shown); however, because of the large macrophage influx CD8+ lymphocytes were reduced as a percentage of total CD45+ leukocytes. In contrast, the proportion of CD4+ T cells was relatively unchanged up to 6 weeks of doxycycline treatment related to a large influx of CD4+CD25+Foxp3+regulatory T lymphocytes (Tregs) ([figure 6A,B](#F6){ref-type="fig"}). By 1 week after initiation of doxycycline treatment, almost 40% of CD4+ lymphocytes were Tregs, and this increase persisted up to 6 weeks after initiation of doxycycline treatment. By real time RT-PCR, we evaluated production of NF-κB-regulated chemokines that could facilitate Treg recruitment. As shown in [figure 6C](#F6){ref-type="fig"}, we identified increased mRNA expression of C-C motif chemokine ligands (CCL) 17, 20, and 22 in lung homogenates of *IKTA* mice after 6 weeks of doxycycline treatment compared with doxycycline-treated *WT* controls.

To test whether CD4+CD25+Foxp3+ Tregs isolated from lungs of doxycycline-treated *IKTA* mice possessed regulatory properties, we assessed their ability to suppress effector T cell proliferation in an allogeneic mixed lymphocyte reaction (MLR) assay ([@R2]). For these studies, CD4+CD25+ cells were isolated from lungs of doxycycline-treated *IKTA* (FVB) mice. Approximately 93% of these cells were also positive for Foxp3 (data not shown). Effector T cells (Teff) from spleens of naïve FVB mice were activated by allogeneic mature dendritic cells and the suppressive effect of CD4+CD25+ T cells on proliferation of Teff cells was evaluated by measuring carboxyfluorescein succinimidyl ester (CFSE) fluorescence. CD4+CD25+ T cells from *IKTA* mice inhibited the proliferation of Teff cells with the most effective suppression observed at Treg:Teff ratios ranging from 1:1 to 1:4 ([figure 7A](#F7){ref-type="fig"}). These results demonstrate that CD4+CD25+Foxp3+ T cells isolated from lungs of *IKTA* mice have immunosuppressive properties characteristic of Tregs.

Since Tregs have been implicated in altered immune surveillance and evasion of malignant cells from immune-mediated destruction, we depleted Tregs using a monoclonal antibody approach to investigate the impact of Tregs on the increased tumorigenesis observed in urethane-treated *IKTA* mice. We established that monoclonal anti-CD25 antibodies were able to substantially reduce the CD4+CD25+ lymphocyte population ([figure 7B](#F7){ref-type="fig"}). To test contribution of Tregs in lung carcinogenesis, we treated our mice with anti-CD25 or isotype control antibodies for 4 months. As indicated in [figure 7C](#F7){ref-type="fig"}, Treg depletion did not influence tumorigenesis in *WT* mice, but significantly blocked the increased tumor formation observed in *IKTA* mice. No differences in tumor size or appearance were identified. Next we investigated whether the influx of Tregs observed in *IKTA* mice promotes lung tumorigenesis by impacting the early stages of tumor development. We treated *IKTA* mice with anti-CD25 or control antibodies as described above and analyzed lungs for the appearance of AAH lesions at 6 weeks after injection of urethane. We observed reduced numbers of AAH lesions after depletion of CD25+ cells ([figure 8A](#F8){ref-type="fig"}). In addition, flow cytometry analysis of lungs from these mice confirmed a reduction in Tregs but revealed an increased infiltration with CD8+ lymphocytes ([figure 8B--D](#F8){ref-type="fig"}).

We wondered whether depletion of Tregs in *IKTA* mice could alter Th1/Th2 polarization of lung lymphocytes. Therefore, we isolated T cells from lungs of doxycycline-treated *WT* controls or *IKTA* mice at one week after the injection with anti-CD25 or control antibodies and investigated production of IFNγ and IL-4 in response to stimulation with PMA/ionomycin. Although we found no differences in the percentage of IKTA lymphocytes producing IFNγ or IL-4 after Treg depletion, the proportion of IFNγ producing lymphocytes was lower in *IKTA* lymphocytes compared to controls ([figure 8E,F](#F8){ref-type="fig"}). We next asked whether Tregs could enhance lung tumorigenesis through down-regulation of cytotoxic T lymphocyte responses. To test whether CD8+ lymphocytes could have a role in suppressing tumor formation in *IKTA* mice, we depleted CD8 lymphocytes using anti-CD8 antibodies. Flow cytometry analysis of lung cells confirmed efficient depletion of these cells ([figure 9A](#F9){ref-type="fig"}). As indicated in [figure 9B](#F9){ref-type="fig"}, continuous depletion of CD8 lymphocytes in *IKTA* mice increased the number of lung tumors at 4 month after injection of urethane. Together, these studies suggest that Tregs recruited to the lungs could facilitate urethane-induced tumorigenesis through suppression of cytotoxic CD8 lymphocytes.

DISCUSSION {#S7}
==========

The NF-κB pathway is increasingly recognized as an important player in lung cancer development and progression. Previously, we showed that inhibition of NF-κB signaling reduces lung tumor formation induced by chemical carcinogens ([@R44]), a finding that has been since corroborated and expanded by others in genetic models of lung cancer resulting from oncogenic *Kras* expression ([@R5]; [@R26]; [@R46]). Here, we demonstrate that chronic activation of the NF-κB pathway amplifies tumor formation and can function as the sole tumor promoter in the presence of an initiator (mutagen). The crucial time interval for these effects appears to be the promotion phase of tumorigenesis, leading to increased epithelial cell proliferation and increased premalignant AAH lesions by 6 weeks after urethane injection. A reduction in epithelial apoptosis at later time points may also contribute to increased tumorigenesis in the setting of chronic NF-κB-induced inflammation. We found that Tregs are recruited to the lungs in IKTA mice and that depletion of Tregs reduced tumorigenesis in *IKTA* mice but not in *WT* mice. This finding implicates Tregs as being important for the excessive tumor formation resulting from chronic airway inflammation. Although the role of Tregs in COPD and other chronic airway diseases is not well defined, increased Tregs have been reported in lungs of COPD patients when compared to nonsmokers in several studies ([@R20]; [@R22]; [@R35]; [@R43]), indicating that our findings may have relevance to the increased tumor risk associated with chronic inflammatory diseases of the lungs.

Accumulating evidence supports the idea that crosstalk between epithelial and immune cells in the tumor microenvironment sets up a cycle of communication with pro-tumorigenic effects. Here, we focused on the ability of epithelial NF-κB pathway activation to modify the microenvironment in a pro-tumorigenic manner through recruitment and activation of immune/inflammatory cells. Because of the substantial increase in Tregs observed in our mouse model and published reports of elevated numbers of these cells in lungs of patients with COPD ([@R43]), we investigated the role of Tregs in exaggerated tumorigenesis in *IKTA* mice. For many tumor types, there is a clear connection between abundant accumulation of Tregs in established tumors and poor clinical outcome ([@R12]; [@R29]; [@R37]; [@R50]); however, there is little known regarding the role of Tregs in tumor promotion. A prior study showed that rapamycin treatment reduced lung tumor formation in A/J mice treated with N-nitrosamine \[4-(methylnitrosamino)-1-1(3-Pyridyl)-butanone\] in association with decreased numbers of Foxp3+ cells in the lungs ([@R16]). In addition, crossing Scurfy mice, which bear a loss-of-function mutation in the *Foxp3* gene, with mice expressing oncogenic *Kras* resulted in fewer lung tumors ([@R16]). We found that functional Tregs were recruited to the lungs in an NF-κB dependent manner in *IKTA* mice. To investigate the role of Tregs in lung tumorigenesis we exploited well known approach of cell depletion using anti-CD25 mAb. These antibodies have been widely used for isolation of Tregs as well as for elimination of Tregs *in vivo*. However, conflicting evidence has ben reported regarding the nature of the inhibitory effects of anti-CD25 mAb treatment on the Treg population. Kohm et al. showed that treatment with CD25 antibody (clone 7D4) resulted in functional inactivation rather than depletion of Tregs ([@R19]). Other groups have demonstrated depletion of Tregs after injection of anti-CD25 antibodies using clone PC61, as was used in our studies ([@R39]; [@R45]; [@R54]). By reducing the number of Tregs in our model, we found that these cells contribute to the increased tumor formation in *IKTA* mice. Interestingly, depletion of Tregs had no effect on tumor formation in urethane-treated *WT* mice, suggesting that Tregs can enhance tumor promotion but are not necessary for urethane-induced tumorigenesis. Therefore, recruitment of Tregs may be one important mechanism by which chronic airway inflammation facilitates tumor development. Tregs may facilitate cancer cell evasion from immune-mediated destruction through a variety of mechanisms, including elaboration of an immunosuppressive cytokine profile as well as impaired production or function of tumor-specific T cells ([@R13]; [@R30]). Our findings suggested that the impact of Tregs on lung tumorigenesis in *IKTA* mice is unlikely to be explained by phenotypic alterations of effector CD4 lymphocytes. Rather, based on the increased influx of CD8 lymphocytes observed after CD25 depletion in *IKTA* mice, we speculate that suppression of cytotoxic CD8 lymphocyte responses contributes to the pro-tumorigenic effects of Tregs in our model.

While the absolute number of lung tumors induced by urethane was lower in the tumor-resistant C57BL/6 background compared to the more susceptible FVB strain, NF-κB activation resulted in proportionally similar increases in tumorigenesis in both strains of *IKTA* mice compared to strain-specific controls. Thus, NF-κB-induced chronic inflammation does not appear to completely overcome genetic resistance to lung tumorigenesis. This observation is in accord with observations in humans; only one fifth of heavy smokers develop lung cancer ([@R3]; [@R9]). While the explanation for individual differences in susceptibility to carcinogenic exposure is a focus of intense research, it is likely that environmental influences, like chronic airway inflammation, can alter underlying genetic risk ([@R1]; [@R11]). Therefore, interventions to modulate inflammatory pathways or mediators could be effective for cancer chemoprevention regardless of genetic susceptibility.

An association between chronic inflammation and cancer has been recognized in many human organ systems, including the lungs ([@R38]). In addition to patients with COPD, chronic airway inflammation occurs in a large number of current and ex-smokers without airway obstruction ([@R15]; [@R21]; [@R51]). Also, environmental exposure to air pollutants, such as diesel exhaust particulates, has been shown to cause or exacerbate airway inflammation and induce NF-κB activation in bronchial epithelial cells ([@R8]; [@R25]). Therefore, the influence of NF-κB and chronic inflammation on tumorigenesis in the lungs may be broadly important in promoting lung cancer. However, more work is needed to determine the impact of NF-κB signaling on lung carcinogenesis in humans. The NF-κB pathway or components of the chronic inflammatory environment in the lungs, like Tregs, might serve as important targets for cancer chemoprevention strategies.

MATERIALS AND METHODS {#S8}
=====================

Animal Models {#S9}
-------------

*IKTA* mice (IKKβ Trans-Activated) selectively expressing a constitutively active form of human IKKβ in airway epithelium have been reported previously ([@R10]). We used sex matched *IKTA* mice and *WT* littermate controls (weighing 20--25 grams) on the original FVB background as well as transgenic mice backcrossed \>9 generations into the C57BL/6 background. To activate transgene expression, mice were provided *ad lib* with 0.5 mg/ml doxycycline (dox) in drinking water. To induce tumors, urethane was given by a single IP injection (1 g/kg). In other studies, 3-methylcholanthrene (MCA) (15 μg/g) was given by a single IP injection and butylated hydroxytoluene (BHT) (200 μg/g) or vehicle (corn oil) was delivered by 8 weekly IP injections. NF-κB reporter transgenic *HLL* mice on FVB background have been used for bioluminescence imaging as previously reported ([@R44]; [@R53]). All mouse experiments were approved by the Vanderbilt University Institutional Animal Care and Utilization Committee.

In vivo depletion of Tregs and CD8 lymphocytes {#S10}
----------------------------------------------

CD25+ Treg cells were depleted using modifications of previously published protocols ([@R14]). For depletion 500 μg of monoclonal anti-CD25 antibody (clone PC61; ATCC) or control IgG (Jackson ImmunoResearch) were injected IP into *WT* or *IKTA* mice at day -1 (prior to injection of urethane), day 6, and every 2 weeks for 16 weeks. CD8 cells were depleted with IP injection of 400 μg of 2.43 (anti-CD8) Abs on Day -1. Thereafter, maintenance injections of 200 mg of antibody were given weekly as described([@R17]). The efficacy of the depletion was determined by FACS analysis of single cell suspension from lungs of doxycycline-treated *IKTA* mice.

BAL collection and cell counts {#S11}
------------------------------

BAL was performed with 3 aliquots of 800 μl sterile normal saline. Fluid was combined and centrifuged at 400× g for 10 min to separate cells from supernatant. Total and differential cell counts were done as previously described ([@R44]).

Flow Cytometry {#S12}
--------------

Lungs were digested in RPMI medium containing collagenase XI (0.7 mg/ml; Sigma-Aldrich) and type IV bovine pancreatic DNase (30 μg/ml; Sigma-Aldrich). After elimination of red blood cells using RBC Lysis Buffer (BioLegend), cells were stained with antibodies: CD4-FITC (RM4-5), CD25-APC (PC61.5), FoxP3-PE (FJK-16s) from e-Bioscience, CD45- Pacific Blue (30-F11, Invitrogen), CD3-V500 (500A2), CD8- Alexa Fluor 700 (53-6.7), IFNγ--PE-Cy7 (XMG1.2), IL-4 - PE (11B11) from BD Bioscience. For determining Th1/Th2 polarization, T cells were isolated from lungs of doxycycline-treated *IKTA* mice using T-cell enrichment columns (R&D) and re-stimulated with PMA (1ng/ml) and ionomycin (1uM) for 6 h in the presence of Golgi-stop (BD Biosciences) at 37°C, 5% CO2. After staining with CD3 and CD4 antibodies, cells were permeabolized and processed for intracellular staining using anti-IFNγ, IL-4 and FoxP3 antibodies. Cells were analyzed using a LSR II flow cytometer (BD Biosciences), and data were analyzed using Flow Jo 7.2 software (Tree Star).

Lung tumor enumeration {#S13}
----------------------

Surface tumors were counted under a dissecting microscope by two readers blinded to the samples and averaged, as previously described ([@R44]). Tumor diameter was determined using digital calipers (Fisher Scientific).

Histology, immunohistochemistry and analysis {#S14}
--------------------------------------------

Lung sections (5 μm) were stained with H&E or used for immunohistochemistry. Sections were stained with antibodies against PCNA (Invitrogen Corporation, Carlsbad, CA) or active caspase-3 (Abcam Inc., Cambridge, MA). For proliferation analysis animals received an IP injection of 100 μl of BrdU (20 mg/ml, ACROS Chemical Co.) 2 hours prior to sacrifice. Lung sections were stained with rat anti-BrdU antibody (1:400; Accurate Chemical Co.). Proliferation indices were calculated by counting the number of BrdU-positive nuclei per total nuclei in tumors.

Real-time PCR {#S15}
-------------

Total RNA was isolated from lung tissue using the RNeasy Mini kit (Qiagen, Valencia, CA) according to manufacturer's specifications. DNase-treated samples were subjected to quantitative RT-PCR using SYBR Green PCR Master Mix (Applied Biosystems). PCR primers used were: CCL17 forward 5′-TGCTTCTGGGGACTTTTCTG -3′, reverse 5′-CATCCCTGGAACACTCCACT -3′; CCL20 forward 5 ′-TTTTGGGATGGAATTGGACAC-3′, reverse 5′-TGCAGGTGAAGCCTTCAACC-3′; CCL22 forward 5′-GGCACCTATCCAGTGCCACA-3 ′, reverse 5 ′-TGGTGGACCAGCCTGAAACTC -3′; GAPDH forward 5′ -- TGAGGACCAGGTTGTCTCCT -- 3′, reverse 5′ -- CCCTGTTGCTGTAGCCGTAT -- 3′. The relative mRNA expression in each sample was normalized to GAPDH and presented using the comparative Ct method (2^ΔCt^).

Western blot analysis {#S16}
---------------------

Protein extracts from tissue homogenates (100 μg) were separated on a polyacrylamide gel and transblotted for detection of FLAG-cIKKβ. Proteins were separated on a 10% acrylamide gel and anti-FLAG antibodies (anti-FLAG conjugated with HRP M~2~ monoclonal antibody, Sigma-Aldrich, St. Louis, MO) were used ([@R10]). Antibodies to p42/p44 MAP Kinase (Cell Signaling Technology, Danvers, MA) were used as a loading control. Horseradish peroxidase was detected by chemoluminescence using Lumi-Light^PLUS^ western blotting substrate (Roche Diagnostics, Indianapolis, IN).

Mixed lymphocyte reaction (MLR) {#S17}
-------------------------------

An allogeneic MLR protocol was adapted from Banerjee and colleagues ([@R2]) using CD4+CD25- effector T cells (Teff) from spleens of naïve FVB mice (1 × 10^5^/well) as responders and allogeneic mature bone marrow-derived dendritic cells from C57BL/6 mice as stimulators. Dendritic cells were obtained by culturing bone marrow cells in DMEM (Gibco), supplemented with 10% FBS, antibiotics, 50 mM 2-ME (Gibco), recombinant GM-CSF (20 ng/ml, Miltenyi) and IL-4 (20 ng/ml, Miltenyi) and matured by incubation for 24 hours with LPS (1 μg/ml) added on Day 7. The ratio between the dendritic cells and CD4+CD25- Teff cells was 1:10. To assess T cell proliferation, freshly isolated Teff cells were labeled with CFSE (5 μM; Invitrogen). The suppressive function of CD4+CD25+ T cells (Treg) was tested on the proliferation of CFSE-labeled Teff cells. The ratio of Teff:Treg cells varied between 1:1 and 1:32. CD4+CD25+ Tregs from lungs of *IKTA* mice treated for 1 week with 0.5 g/L of doxycycline were isolated using a Treg isolation kit (Miltenyi Biotec). The proliferation of viable CFSE-labeled Teff cells was assessed by flow cytometry. Dead cells were excluded from analysis based on staining with DAPI (Invitrogen).

Statistics {#S18}
----------

Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA). Pair-wise comparisons were made using Welch's t test. Comparisons among groups were done by one-way ANOVA using Tukey's post test. Results are presented as mean ± standard error of the mean. *P* values \< 0.05 were considered significant.
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![Persistent NF-κB activation in airway epithelium results in chronic inflammation\
A) Total number of polymorphonuclear leukocytes (PMNs), macrophages (macs), and lymphocytes (lymphs) obtained by bronchoalveolar lavage (BAL) in *IKTA* transgenic mice in the absence of doxycycline (dox) treatment or after 2 or 4 weeks on dox (n = 4--6 per group). B) Western blot from whole lung tissue to identify expression of the FLAG-tagged transgene in *IKTA* mice, normalized for p42/44 MAP kinase.](nihms325598f1){#F1}

![NF-κB activation in IKTA transgenic mice enhances lung tumorigenesis after urethane injection\
A) Timeline for treatment of mice with a single IP injection of carcinogen (urethane, 1 g/kg) and doxycycline (dox) during three different time intervals. B) *WT* and *IKTA* mice were treated with dox for 2 weeks prior to urethane and continued for another 3 weeks (week -2--3). *WT* mice without dox were used an additional control (n=9--11 per group, \*=p\<0.01 compared to the other groups). C) *WT* and *IKTA* mice were treated with dox beginning at 4 weeks after urethane and continued until the time of harvest (week 4--16) (n=14 for *WT* and 7 for *IKTA*, \*=p\<0.01 compared to *WT*). D) *WT* and *IKTA* mice treated with dox beginning 2 weeks before urethane and continuing for the duration of the experiment (week -2--16). A group of *IKTA* mice without dox treatment (*IKTA*) was included (n=7--9 per group, \*=p\<0.01 compared to the other groups).](nihms325598f2){#F2}

![Characterization of lung tumors in WT and IKTA mice\
A) Lung sections from urethane-treated *IKTA* mice and *WT* controls treated with doxycycline throughout the course of tumor formation (week -2--16) were sectioned at four predetermined depths and tumors were counted on each H&E stained section. B) Morphometric analysis of tumor diameter was assessed as the mean of 4 separate diameter measurements of all tumors (taken at 45^0^ angles). C) Total number of macrophages (macs), lymphocytes (lymphs), and polymorphonuclear leukocytes (PMNs) in BAL from *IKTA* and *WT* mice (n=6 per group, \*=p\<0.05 compared to *WT*). D) Bromodeoxyuridine (BrdU) was injected IP 2 hours prior to sacrifice and the percentage of BrdU positive cells per total number of nuclei in tumors was assessed.](nihms325598f3){#F3}

![NF-κB functions as a specific tumor promoter and enhances tumorigenesis in a resistant mouse strain\
A) Bioluminescent detection of NF-κB activity in the lungs of NF-κB reporter mice after a single IP injection of MCA (15 μg/g) or BHT (200 μg/g) (n=3 for MCA and 4 for BHT, \*=p\<0.05 compared to baseline and MCA). B) Lung surface tumor counts in *WT* and *IKTA* mice treated with a single IP injection of MCA (15 μg/g) ± 8 weekly IP injections of BHT (200 μg/g) or vehicle (corn oil) control ± doxycycline (dox) treatment from week -2--16. Mice were sacrificed at 16 weeks after MCA treatment (n=6--8 mice per group, \*=p\<0.01 compared to MCA treatment alone). C) Lung surface tumor counts in *WT* (C57BL/6) mice and *IKTA* mice (C57BL/6 background) treated with dox for 6 months after a single IP injection of urethane (n=10--11 per group, p\<0.05).](nihms325598f4){#F4}

![Increased number of atypical adenomatous hyperplasia (AAH) lesions in lungs of IKTA mice is associated with increased proliferation of cells in lung parenchyma\
A) *WT* and *IKTA* mice were treated with doxycycline (dox) beginning 2 weeks before urethane and continuing until time of harvest at 3, 6, or 9 weeks post-urethane. AAH lesions were counted on H&E stained lung sections (n=6--12 per group, \*=p\<0.05 compared to *WT* mice at the same time point). B) Illustration of characteristic AAH lesions in *WT* and *IKTA* mice. C) PCNA scoring was done on H&E stained lung sections. (n=6--12 per group, \*=p\<0.05 compared to *WT* at the same time point). D) Immunohistochemistry for PCNA showing nuclear staining (brown) predominantly in type II alveolar epithelial cells throughout lung parenchyma (original magnification x400). E) Active caspase-3 scoring on lung sections from dox-treated *WT* and *IKTA* mice treated continuously with dox and harvested at 9 weeks post-urethane (n=8 for *IKTA* and 10 for *WT*, \*=p\<0.05). Semi-quantitative scoring of PCNA or active caspase-3 staining was performed on ten sequential, non-overlapping tissue fields of lung parenchyma evaluated under x400 magnification. Each tissue field was scored using a 0 to 4 point system (0 -- no positive cells; 1 -- ≤5% positive cells; 2 -- 5--10% positive cells; 3 -- 10--25% positive cells; 4 -- \>25% positive cells).](nihms325598f5){#F5}

![NF-κB activation in IKTA transgenic mice increases the numbers of CD4+CD25+Foxp3+ regulatory T cells in the lungs\
A) Representative flow cytometry plots for identification of CD4+ T cells, CD8+ T cells, and CD4+CD25+Foxp3 Tregs in lungs of *WT* and *IKTA* mice treated with doxycycline (dox) for 3 weeks. B) Total CD4+ T cells, CD8+ T cells, and CD4+CD25+Foxp3 Tregs identified by flow cytometry in lungs from untreated *WT* mice and *IKTA* mice 1--6 weeks after initiation of dox treatment (n≥4 per group for each time interval, \*=p\<0.01). C) Relative mRNA expression of CCL17, CCL20 and CCL22 in lung homogenates prepared from *WT* and *IKTA* mice after 6 weeks of dox treatment (n=7 for *IKTA* and 10 for *WT*, \*=p\<0.01).](nihms325598f6){#F6}

![Tregs in the lungs of IKTA transgenic mice exhibit immunosuppressive properties and enhance lung carcinogenesis\
A) CD4+CD25+ T cells from lungs of dox-treated *IKTA* mice impair the ability of allogeneic dendritic cells (DC) to induce proliferation of CFSE-labeled responder CD4+CD25- T cells (Teff). B) Flow cytometry assessment of lung-infiltrating T cells (from CD45+CD3+ gate) in *IKTA* mice at 1 week after a single IP dose of 500 μg of anti-CD25 (PC61) or isotype control antibodies. C) Surface tumors per left lung from mice treated with anti-CD25 antibodies (CD25) or isotype control antibodies (IgG) the day prior to urethane treatment and on day 6, followed by repeated IP injections every 2 weeks for 4 months (n=5--7 per group, \*=p≤0.05 for *IKTA* mice treated with anti-CD25 Ab compared to *IKTA* mice treated with isotype control Ab).](nihms325598f7){#F7}

![Depletion of Tregs in IKTA mice increases infiltration of lungs with CD8 lymphocytes and reduces the number of atypical adenomatous hyperplasia (AAH) lesions\
A) Photomicrographs of lung sections demonstrating AAH lesions at 6 weeks post-urethane in *IKTA* mice treated with anti-CD25 antibodies (CD25) or isotype control antibodies (IgG) per protocol (original magnification x200). B--D) Percentages of total CD4+ T cells, CD8+ T cells, and CD4+ Foxp3+ Tregs identified by flow cytometry in lungs from anti-CD25 or isotype control antibody-treated *IKTA* mice at 6 weeks after injection of urethane (1 week after last antibody dose) (n=4 per group, \*=p\<0.05). E,F) Percentages of CD4+Foxp3-IL-4+ and CD4+Foxp3-IFNγ+ lymphocytes isolated from lungs of doxycycline-treated *IKTA* mice at 1 week after a single IP dose of 500 μg of anti-CD25 (PC61) or isotype control antibodies. Cells were re-stimulated with PMA/ionomycin for 6 hours in vitro and analyzed by flow cytometry.](nihms325598f8){#F8}

![Depletion of cytotoxic CD8 lymphocytes in IKTA mice enhances lung carcinogenesis\
A) Flow cytometry assessment of lung-infiltrating lymphocytes from total CD45+CD3+ gate in *IKTA* mice at 1 week after a single IP dose of 200 μg of anti-CD8 (2.43) or isotype control antibodies. B) Surface tumors per left lung from mice treated with anti-CD8 or isotype control antibodies (IgG) per protocol for four months (n=5 per group, \*=p≤0.05).](nihms325598f9){#F9}
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